Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells. It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia. MS is extremely uncommon in acute promyelocytic leukemia (APL). In the case described here, MS was the sole site of APL relapse and the cause of spinal cord compression. The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete remission. He was treated with excision of the mass followed by local radiotherapy. Systemic treatment was also given with combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular remission.
1. Introduction
Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells [1]. It can occur in association with myelogenous leukemia, myeloproliferative disorders, and myelodysplasia. MS has different modalities of presentation and can affect any organ. It may occur otherwise in healthy individuals who subsequently develop an overt typical myelogenous leukemia [1, 2]. MS can also develop in leukemia patients concurrently with or after diagnosis, or as a manifestation of disease relapse [3, 4]. The WHO recognizes three major variants of MS based on the predominant cell type and the degree of maturation, namely respectly, a myeloblast variant, with a mix of myeloblasts and promyelocytes variant, and more differentiated variant with promyelocytes and more mature granulocytes [5]. Acute promyelocytic leukemia (APL) accounts for approximately 10% of acute myeloid leukemia (AML) and cases of MS due to APL have been only occasionally reported [1–4]. We report the case of a patient with APL who presented right paraparesis after 7 years of complete remission. The patient had a MS with paravertebral localization as the only site of APL relapse.
2. Case Report
In November 1999, a 38-year-old male presented with a history of recurrent episodes of gum bleeding. Physical examination was unremarkable, but a complete blood count showed Hb 6.1 g/dL, WBC 1×109/L, and platelets 2×109/L. Microscopic examination of a blood smear showed 8% hypergranular promyelocytes, with Auer rods. At examination of bone marrow aspirate a diffuse infiltration by atypical promyelocytes was apparent. The immunophenotype profile of leukemic cells was consistent with APL (CD33+ve, CD45+ve, HLA-DR-ve, CD34-ve, CD16-ve, and CD56-ve). Cytogenetics revealed the characteristic t(15;17) (q22;q21-q22) and the RT-PCR assay showed the typical PML/RARα fusion gene thereby confirming the diagnosis of APL [6]. The patient was treated with all-trans retinoic acid (ATRA) 45 mg /m²/day ber 30 days and idarubicin (IDA) 12 mg/m²/day on days 2, 4, 6, and 8. On day 20, the patient had severe pulmonary distress that was consistent with an ATRA syndrome [7]. This was successfully managed with high-dose dexamethasone and ATRA discontinuation. Despite that, following induction, bone marrow evaluation revealed a morphologic and molecular picture of complete remission. The patient received 3 additional courses of chemotherapy as consolidation and completed his treatment in July 2002. Five years later in July 2007, the patient presented with right chest pain and progressive right paraparesis in a few-week duration. An MRI of the spine revealed a solid extramedullary intraspinal mass extending between T6 and T8. Diagnostic workup including coagulation profile and complete blood counts was normal, and neither atypical promyelocytes nor blast cells were detected in peripheral blood and bone marrow. In addition, PCR analysis for PML/RAR transcripted on bone marrow cells confirmed a status of molecular remission. Cord decompression was performed with total laminectomy and excision of an extradural soft tissue mass of 4 cm × 5 cm × 5 cm. Histopathology examination showed diffuse infiltration by monomorphic, medium-sized, neoplastic cells with round shaped deeply indented or bilobated nuclei with dispersed chromatin, inconspicuous nucleoli, and basophilic cytoplasm. The immunophenotype characteristics of neoplastic cells were as follows: myeloperoxidase and CD117 (c-KIT) were strongly positive; CD45 was weakly and focally expressed while CD34, CD31, CD20, CD79a, CD3, CD56, and CD15 were negative. Cytogenetic studies showed (Figure 1) t(15;17) (q22;q21-q22) with PML/RARα fusion gene as demonstrated by FISH LSI with PML/RARα probe dual color (Dual fusion translocation probe, Vysis/Abbot). Since the disease was localized to the spine, the patient underwent a local radiotherapy with 36 Gy.
(a) The pictures show adipose and fibrous tissue with dense and diffuse infiltrate of monomorphic PML cells (H\E, 20×). (b) FISH revealed the presence of the reciprocal and balanced t(15;17) on PML cells (arrow).
Systemic therapy was also started on an outpatient basis with combined ATRA and arsenic trioxide (ATO) for a total of 5-month cycles according to the scheme reported by Estey et al. [8]. The patient were able to achieve and maintain a second complete hematologic remission. Currently, he is still in remission and well 20 months since the end of treatment.
3. Discussion
Extramedullary disease (EMD) at diagnosis or at relapse develops in 3%–8% of patients with acute myelogenous leukemia, more frequently in those with myelomonocytic and monocytic morphology [9–11] (M4 and M5 French- American- British subtypes). Its occurrence in APL is relatively rare but after the advent of ATRA it is increasingly reported at time of relapse [11–29]. The case reported here, is a rare case of CNS isolated relapse [13]. The patient presented with neurologic symptoms due to a paravertebral mass after 7 years of complete remission. He entered a second prolonged clinical and molecular remission after local radiotherapy followed by a combination of ATRA and ATO. This case represents the second report of MS resulting in spinal cord compression due to APL extramedullary relapse. The other case, reported by Tsimberidou et al. [30], was a man who remained in complete remission for 3 years after treatment of APL. This patient later developed paraplegia due to a paravertebral mass at the level of T7-T8. Following decompression laminectomy, an isolated extramedullary promyelocytic relapse was diagnosed. The bone marrow was not involved. The patient was treated with local radiotherapy followed by ATRA and idarubicin, achieving a short second remission. He subsequently developed a second relapse with marrow and skin involvement.
The occurrence of EMD has long been considered a rare event in APL patients treated with chemotherapy alone, whereas this phenomenon has increasingly been reported in the ATRA era [5, 9, 38]. The question arises as to whether treatment of APL with ATRA predisposes patients to the development of EMD [38, 51]. This question is still open, as various trials have shown contrasting results. Wiernik et al. [3] suggested that extramedullary APL occurs more frequently after ATRA than other therapies. Ko et al. [23] demonstrated that patients receiving ATRA induction had a 2.1 increased relative risk of EMD compared with those with chemotherapy alone. In a literature review by Bae et al. [51], only three of 21 cases with CNS relapse received systemic chemotherapy without ATRA. Among 172 patients with APL treated at MDACC between 1980 and 2003, a total of three patients relapsed with isolated EMD and it occurred exclusively in patients who had received ATRA-containing induction regimens [51]. Ohno et al. [52] noted that EM relapse was absent from all 37 patients with relapsing APL in the Japanese chemotherapy only studies, while it was seen in 8% of 121 patients in the chemotherapy plus ATRA protocols and this raised the possibility that the doses of chemotherapy given with ATRA-based regimens are less intensive than those previously used and thus may not reach therapeutic levels in the EM tissues. This could be particularly relevant to protocols without cytarabine. A relationship between EMD and ATRA treatment has been suggested. Two possible explanations are considered. The first suggests a direct effect of ATRA on adhesion molecules resulting in increased infiltration capability of APL leukemia blasts [23]. The second postulates the occurrence of MS in relapsed patients as a consequence of the prolonged survival [38]. In a study of the GIMEMA [38], the authors found no statistical difference in the frequency of extramedullary involvement between patients treated with or without ATRA. EMD was documented in 5% and 12% of patients included in the LAP0389 and AIDA protocol, respectively, with no statistical difference. In particular, the five EMD localizations in the LAP0389 study were in the CNS (1 patient), the skin (3 patients), and the middle ear (1 patient). Of the 16 EMD relapses in the AIDA study, 10 involved the CNS and six involved other extramedullary sites (the skin in 3, the middle ear in 2, and the lung in 1). Thus CNS disease at relapse seems frequent among the AIDA treated patients (8% versus 1%) [39]. Breccia et al. [50] described three adult patients with middle ear localizations at relapse. They had been previously treated with ATRA and CT. Their characteristics are shown in Table 1.
Clinical features of patients with MS in APL.
References
No. cases
disease status
Time since
Site of involvement
diagnosis/EMD relapse (months)
Fukushima et al. [31]
1
onset
cerebellum + hematological
Worch et al. [32]
1
onset
lytic lesions of humerus, tibia, femur + molecular hematological
Ajarim et al. [33]
1
onset
thymus + hematological
Savranlar et al. [34]
1
onset
thoracic-epidural
Brown et al. [35]
1
onset
optic nerve + hematological
Agarwal et al. [36]
1
relapse
31
hip + hematological
Disel et al. [37]
1
relapse
9
pleura
Tsimberodou et al. [30]
1
relapse
36
thoracic spine
Specchia et al. [38]
1
relapse
NA
lung + hematological
3
relapse
155
mastoid + hematological
Latagliata et al. [39]
71
mastoid + mol hematological
61
mastoid
3
relapse
7
subcutaneous nodules at sternal manubrium + wrist at level of the radial artery pulse + site of intravenous catheter scar+ mol hematological
Sanz et al. [40]
6
subcutaneous nodules at jugular catheter scar + wrists at level of the radial artery pulse + molecular hematological
1st testicular -2nd retroperitoneal nodes, psoas muscle and skin
Skarin et al. [47]
1
relapse
8
CNS + hematologic
Leoni et al. [48]
2
relapse
NA
(1) central nervous system + middle ear + lymph nodes.
(2) skin + lymph nodes
Ammatuna et al. [49]
1
relapse
NA
1st and 2nd -scalp + mol hematological 3rd mol hematological + breast
Breccia et al. [50]
7
relapse
5 from CR
(1) left auricular canal + mastoid + mol hematological
69
(2) left mastoid + mol hematological
58
(3) left mastoid
9
(4) left mastoid + hematologic
12
(5) left mastoid + hematologic
64
(6) right auricular canal
6 from 2nd CR
(7) right mastoid + CNS + mol hematological
NA: not available; mol: molecular; CR: complete remission;
Similarly, C. Samanez et al. [53] reported 7 cases of EMD relapse in APL patients receiving chemotherapy (CT) alone (102 patients) or combined with ATRA (155 patients). EMD relapse rate was 4.4% in the CT group and 8.7% in the group CT plus ATRA, with no statistical differences. EMD localizations were in soft tissues (3 patients), the CNS (2 patients), the tonsils (1 patient), liver (1 patient), and the testis (1 patient). De Botton et al. [54] analyzed EMD relapse occurring in patients with APL treated with ATRA and CT. Of 740 patients included in three multicenter trials (APL91, APL93 trials, and PETHEMA 96) 10 patients developed EMD relapse. Of these, 9 were in the CNS and one in the skin. Only two patients had isolated EMD relapses. A significant correlation could be found between high WBC count and the risk of CNS relapse. More recently, Casanova et al. [55] reported a similar pattern of increased CNS EMD relapse in APL patients treated with ATRA and CT. EMD relapse was found in 8 of 74 (15%) APL patients (CNS: 5, external ear: 3). Together, these studies confirm that the CNS is the preferential site of extramedullary involvement in APL, raising an issue of whether or not to consider CNS prophylaxis in APL treatment protocols especially in patients presenting with hyperleukocytosis, as suggested by the expert panel of the European Leukemia Net. However, the benefit of this policy has not been established in prospective studies [56].The occurrence of the ATRA syndrome was recognized to be a significant risk factor for EMD involvement at relapse [57]. Since APL cells, in patients affected by ATRA syndrome, infiltrate multiple tissues and organs, including the lung and the skin, it was hypothesized that ATRA could promote the migration of differentiating blasts into the skin, the CNS, and other tissues which represented a reservoir of viable blasts. These cells could later proliferate and result in an EMD recurrence [9, 11, 23, 27, 57]. Others have found that elevated WBC count (>10×109 L) on presentation [55], predominance of the PML/RARα bcr3 type, and mirogranular morphology [50] are considered as risk factors.
Management of relapse in the CNS and other extramedullary sites in patients with APL is a challenging issue for which there is a notable lack of information. EMD relapse, including in the CNS, can occur either in isolation or associated with BM involvement as a first relapse, and also after one or more hematologic relapses. Optimal management and outcome of APL patients in these different situations have not been critically assessed. In case of granulocytic sarcoma, wherever it is localized, radiation and intensive systemic therapy might be considered.
Before the demonstration of the striking activity of ATO in APL, salvage therapy usually consisted of the readministration of ATRA and chemotherapy for induction, generally containing high-dose cytarabine and an anthracycline, followed by further chemotherapy and/or hematopoietic stem cell transplantation (HSCT) [58–60]. Confirmation of the high and sustained efficacy of ATO in patients with relapsed/refractory APL has been provided by more recent studies [61, 62]. CR rates in these trials were 80%–90% and, in those studies that evaluated survival, 50%–70% of patients were alive at 1 for 3 years. Current evidence suggests that the use of at least 2 cycles of ATO results in the achievement of second molecular CR in nearly 80% of cases [63]. The best consolidation strategy after ATO induced second remission is unknown; options include continued treatment with repeated cycles of ATO, the use of standard chemotherapy in combination with ATRA and/or ATO, and HSCT. For patients unfit to proceed to HSCT, the available options include repeated cycles of ATO with or without ATRA/standard chemotherapy.
The central nervous system (CNS) is the commonest site of extramedullary disease in APL and at least 10% of hematologic relapses are accompanied by CNS involvement [11]. Because the majority of CNS relapses occur in patients presenting with hyperleukocytosis some strategies include CNS prophylaxis for patients in this particular high-risk setting. For such patients, it is advisable to postpone CNS prophylaxis until after the achievement of CR because lumbar puncture at presentation and during induction is extremely hazardous. However, the benefit of this policy has not been established. For patients without hyperleukocytosis, in whom the risk of CNS relapse is extremely low, there is a general consensus to avoid CNS prophylaxis.
CNS prophylaxis for patients in this particular high-risk setting. For such patients, it is advisable to postpone CNS prophylaxis until after the achievement of CR because lumbar puncture at presentation and during induction is extremely hazardous. However, the benefit of this policy has not been established. For patients without hyperleukocytosis, in whom the risk of CNS relapse is extremely low, there is a general consensus to avoid CNS prophylaxis.
In conclusion, the increasing number and special pattern of EMD involvement in relapsing APL patients emphasize its importance in the differential diagnosis of EMD localization in patients with history of APL. they also highlight the need for understanding the underlying pathogenesis and predisposing factors, as well as for selecting the optimal treatment approach.
NeimanR. S.BarcosM.BerardC.Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases1981486142614372-s2.0-0019490812MenasceL. P.BanerjeeS. S.BeckettE.HarrisM.Extra-medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases199934539139810.1046/j.1365-2559.1999.00651.x2-s2.0-0033026884WiernikP. H.De BellisR.MuxiP.DutcherJ. P.Extramedullary acute promyelocytic leukemia19967825BenekliM.SavasM. C.HaznedarogluI. C.DündarS. V.Granulocytic sarcoma in acute promyelocytic leukemia1996221-21831852-s2.0-0030011616JaffeE. S.HarrisN. L.SteinH.VardimannJ. W.2001105London, UKIARC PressFenauxP.ChomienneC.DegosL.Acute promyelocytic leukemia: biology and treatment1997241921022-s2.0-0031052186LarsonR. S.rlarson@salud.unm.eduTallmanM. S.Retinoic acid syndrome: manifestations, pathogenesis, and treatment20031634534612-s2.0-003604048010.1016/S1521-6926(03)00043-4EsteyE.Garcia-ManeroG.FerrajoliA.Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia200610793469347310.1182/blood-2005-10-40062-s2.0-33646386643LisoV.SpecchiaG.PoglianiE. M.Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases1998838152215282-s2.0-0030825408TsimberidouA.-M.KantarjianH. M.EsteyE.Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy2003176110011032-s2.0-001949081210.1038/sj.leu.2402958EvansG. D.GrimwadeD. J.Extramedullary disease is acute promyelocytic leukemia1999333-42192292-s2.0-0032946404DegosL.All-trans retinoic acid (ATRA) therapeutical effect in acute promyelocytic leukemia1992465–72012092-s2.0-0026671736KanakuraY.YonezawaT.HamaguchiY.Acute promyelocytic leukemia with an intracerebral mass and meningeal involvement after treatment of non-Hodgkin's lymphoma198759194982-s2.0-0023156825MarraR.StoriS.PaganoL.Central nervous system acute promyelocytic leukaemia: a report of three cases19892231951992-s2.0-0024807672NiaziZ.MoltP.MittelmanA.ArlinZ. A.AhmedT.Leukemic dermal infiltrates at permanent indwelling central venous catheter insertion sites19916810228122832-s2.0-0025954253BaerM. R.BarcosM.FarrellH.RazaA.PreislerH. D.Acute myelogenous leukemia with leukemia cutis. eighteen cases seen between 1969 and 198619896311219222002-s2.0-0024359818LongacreT. A.SmollerB. R.Leukemia cutis: analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes199310032762842-s2.0-0027220375GiraltS.O'BrienS.WeeksE.LunaM.KantarjianH.Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid1994145-64534562-s2.0-0028021575EvansG.GrimwadeD.PrenticeH. G.SimpsonN.Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid19979824374392-s2.0-0030842975MenendezA.GonzalesA.CabreraH.Clinical spectrum of extramedullary acute promyelocytic leukemia200064320120310.1034/j.1600-0609.2000.70424.x2-s2.0-0034099425ByrdJ. C.WeissR. B.Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule1994738210721122-s2.0-0028331418BurryL. D.SekiJ. T.CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid20023612190019062-s2.0-0036894542KoB.-S.TangJ.-L.ChenY.-C.Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia—the occurrence of retinoic acid syndrome is a risk factor1999139140614082-s2.0-0032870982YamauchiK.YasudaM.Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature20029461739174610.1002/cncr.103992-s2.0-0037086557MesaJ. R.EspinosaE.LosadaR.HernandezC.MartinezG.HernandezP.Parotid and central nervous system relapse during complete hematologic remission in acute promyelocytic leukemia19998465655662-s2.0-0033002982SeldonM.EnnoA.Central nervous system relapse in acute promyelocytic leukaemia treated with all-trans retinoic acid1998284462WeissM. A.WarrellR. P.Jr.Two cases of extramedullary acute promyelocytic leukemia: cytogenetics, molecular biology, and phenotypic and clinical studies1994747188218862-s2.0-0027963294MiloneG.InghilterraG.Li GioiF.Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL1999237751KaiT.kai@jinsenkai.or.jpKimuraH.ShigaY.OgawaK.SatoH.MaruyamaY.Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy20068343373402-s2.0-1634437182210.1532/IJH97.05167TsimberidouA. M.EsteyE.WhitmanG. J.Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide,all-trans retinoic acid and gemtuzumab ozogamicin therapies200428991994FukushimaS.TerasakiM.TajimaY.ShigemoriM.Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report2006105691291510.3171/jns.2006.105.6.9122-s2.0-33845509279WorchJ.RitterJ.FrühwaldM. C.Presentation of acute promyelocytic leukemia as granulocytic sarcoma200850365766010.1002/pbc.211902-s2.0-38549155555AjarimD. S. S.Santhosh-KumarC. R.HiggyK. E.El SaghirN. S.Al-MomenA. K.ShipkeyF. D.Granulocytic sarcoma of the thymus in acute promyelocytic leukaemia19901219799SavranlarA.UstündagY.OzerT.A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment20045852512542-s2.0-9144232319BrownD. M.KimuraA. E.OssoinigK. C.WeinerG. J.Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid199299914631467AgarwalN.TepeE. M.MishraA.WardJ. H.Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip2006851074174210.1007/s00277-006-0135-z2-s2.0-33747384990DiselU.YavuzS.PaydasS.SahinB.ZerenH.Extramedullary relapse in the pleura in acute promyelocytic leukemia200344118919110.1080/10428190310000572702-s2.0-0037232441SpecchiaG.Lo CocoF.VignettiM.Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto20011920402340282-s2.0-0035886697LatagliataR.CarmosinoI.BrecciaM.Late relapses in acute promyelocytic leukaemia2007117210610810.1159/0000973852-s2.0-33847067001SanzM. A.LarreaL.SanzG. F.Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukaemia200085758762MagliuloG.FusconiM.PuliceG.Acute promyelocytic leukemia and aural recurrence: the importance of otoscopy in early diagnosis20031771418141910.1038/sj.leu.24029872-s2.0-0038442220Nasilowska-AdamskaB.MajewskiM.SeferynskaI.Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT200712333382-s2.0-43049125544SlavchevaV.LukanovT.TzvetkovN.Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia20081345895922-s2.0-58149350067KaiT.KimuraH.ShigaY.OgawaK.SatoH.MaruyamaY.Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy200683433734010.1532/IJH97.051672-s2.0-33744469061TobitaT.ShinjyoK.YanagiM.TakeshitaA.OhnishiK.OhnoR.Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid19973674844862-s2.0-0030750065ForrestD. L.DalalB. I.NaimanS. C.Testicular relapse of acute promyelocytic leukemia after allogeneic BMT19972086896902-s2.0-0030723878SkarinA.MaS. K.OoiC.CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide—induced remission20001834353437LeoniF.GianfaldoniG.AnnunziataM.Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation20028754854892-s2.0-0036090647AmmatunaE.BorzaP. A.IoriA. P.Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukemia200519347948010.1038/sj.leu.24036322-s2.0-15044359506BrecciaM.PettiM. C.TestiA. M.Ear involvement in acute promyelocytic leukemia at relapse: a disease associated ‘sanctuary’?2002166112711302-s2.0-003406184610.1038/sj/leu/2402497BaeS. H.RyooH. M.ChoH. S.LeeJ. L.LeeK. H.HyunM. S.Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature20041923113142-s2.0-2342569514OhnoR.AsouN.OhnishiK.Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate20031781454146310.1038/sj.leu.24030312-s2.0-0042027816SamanezC.SantillanaS.LeonJ.WachtelA.VallejosC.Instituto de Enfermedades Neoplasicas, Lima, PeruPattern of extramedullary relapse in acute promyelocytic leukemia (APL) in Peruvian patients21Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO '02)2002abstract no. 1090de BottonS.SanzM. A.ChevretS.Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy200620135412-s2.0-003624465210.1038/sj.leu.2404006CasanovaL. A.QuintanaS. M.NeciosupS. P.SamanezC. A.Pattern of extramedullary relapse in latin patients with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and chemotherapy25Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO '07)200718Sabstract no. 1752SanzM. A.GrimwadeD.TallmanM. S.Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet200911391875189110.1182/blood-2008-04-1502502-s2.0-61949441174PatriarcaF.FiliC.GerominA.SperottoA.ProsdocimoS.FaninR.Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia200268531031310.1034/j.1600-0609.2002.01660.x2-s2.0-0036345765EsteveJ.EscodaL.MartínG.Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention200721344645210.1038/sj.leu.24045012-s2.0-33847178763EsteyE. H.Treatment options for relapsed acute promyelocytic leukaemia200316352153410.1016/S1521-6926(03)00039-22-s2.0-0041828178ThomasX.DombretH.CordonnierC.Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation2000146100610132-s2.0-0034046084AuW. Y.LieA. K. W.ChimC. S.Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia200314575275710.1093/annonc/mdg2082-s2.0-0038781797ShigenoK.NaitoK.SaharaN.Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies200582322422910.1532/IJH97.050442-s2.0-27644571560TallmanM. S.Treatment of relapsed or refractory acute promyelocytic leukemia2007201576510.1016/j.beha.2006.11.0022-s2.0-33847234222